|
Karen West
General Manager for Australia and New Zealand, Syneos Health Karen has been in the clinical trial industry for over 30 years of which 20 has been working for Syneos health through acquisition. Prior to joining Syneos Health, Karen gained experience working in a pharmaceutical company, a phase I unit and also in local and global CRO’s.
Whilst Karen has worked extensively in the phase I and first in human clinical trial space, she has also worked in all phases of clinical development through to large scale Phase III and post-marketing studies. Karen West has managed staff globally, regionally and locally and has extensive clinical operations management experience having been responsible for over 150 clinical staff in 11 countries within Asia Pacific. Karen has also managed large teams in project management, business development, contracts and proposals, biometrics and medical writing. |
|
Prior to her current role, Karen was Vice President, Clinical Development and held a global role for Syneos, leading the Clinical Pharmaccology and Bioanalysis project management and CRA teams. In 2020, Karen was nominated for the HBA luminary award for her contributions to Syneos health and as a female leader in the pharmaceutical industry.
In her current role as General Manager, Karen is actively involved with promoting and representing Australia and New Zealand globally, often presenting at conferences and roadshows. Karen reports directly into the Head of APAC and is a member of the Syneos APAC leadership team, Biosimilar consortium and an Asian ERG group leader.
In her current role as General Manager, Karen is actively involved with promoting and representing Australia and New Zealand globally, often presenting at conferences and roadshows. Karen reports directly into the Head of APAC and is a member of the Syneos APAC leadership team, Biosimilar consortium and an Asian ERG group leader.
Advances in Australia
Federal and state government support and promotion, the National Governance Framework, private site networks, patient centricity and diversity and decentralised models … what are the new trends and advances in Australia?
How are these advances benefiting clinical development timelines and quality, improving the collection of data and helping to grow the clinical trial industry. What has worked and what is a work in progress? How relevant are these new initiatives to New Zealand and how do they align with attracting trials to New Zealand and getting new medicines to patients?
This session will review some of the advances in Australia whilst also evoke suggestions on how to promote the New Zealand clinical trial industry and put the country on the global clinical trial stage.
How are these advances benefiting clinical development timelines and quality, improving the collection of data and helping to grow the clinical trial industry. What has worked and what is a work in progress? How relevant are these new initiatives to New Zealand and how do they align with attracting trials to New Zealand and getting new medicines to patients?
This session will review some of the advances in Australia whilst also evoke suggestions on how to promote the New Zealand clinical trial industry and put the country on the global clinical trial stage.
